Rosette-forming glioneuronal tumor: an update

C. T. Anyanwu, T. M. Robinson, J. H. Huang

Research output: Contribution to journalReview articlepeer-review

Abstract

Rosette-forming glioneuronal tumor (RGNT) is a rare and distinct primary nervous system tumor. The literature on this novel neoplasm is sparse and limited to mostly case reports. Reviews on the characteristics of this tumor are fewer and far between with the latest up to a decade old. We thus provide a comprehensive review of recent literature to characterize presenting symptoms, radiological evidence, treatment options, and prognosis of this novel neoplasm. A Medline search for case reports detailing primary rosette-forming glioneuronal tumors was performed. RGNTs are a benign tumor of indolent course with mixed glial and neurocytic components. There is a slight female predominance with mean age of presentation at 23.57 years. Headaches, visual disturbances, and nausea and vomiting are the most common symptoms. Most RGNTs have solid and cystic components, arising most frequently in the fourth ventricle or cerebellum. Management is usually through surgery with gross total resection (GTR) providing better prognosis.

Original languageEnglish (US)
Pages (from-to)623-630
Number of pages8
JournalClinical and Translational Oncology
Volume22
Issue number5
DOIs
StatePublished - May 1 2020

Keywords

  • Benign
  • Brain tumor
  • Cerebellar mass
  • Posterior fossa neoplasm
  • RGNT
  • Rosette-forming glioneuronal tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Rosette-forming glioneuronal tumor: an update'. Together they form a unique fingerprint.

Cite this